MGMT and glioblastoma: In the GBM AGILE trial, regorafenib was tested in newly diagnosed GBM patients without MGMT promoter methylation, who were randomized against standard treatment with temozolomide, and in recurrent GBM patients, who were randomized against treatment with lomustine.